N (%) | |
Recanalization time, min (N=137) | |
0–60 | 54 (39.4) |
>60 | 83 (60.6) |
Treatment (N=140) | |
IV tPA | 15 (10.7) |
IA tPA | 74 (52.9) |
IV + IA tPA | 37 (26.4) |
No IV or IA tPA | 14 (10.0) |
mRS at 90 days (N=130) | |
0 | 17 (13.1) |
1 | 26 (20.0) |
2 | 15 (11.5) |
3 | 19 (14.6) |
4 | 18 (13.9) |
5 | 8 (6.2) |
6 | 27 (20.8) |
mRS at 90 days categorized as good outcome (N=130) | |
mRS 0–2 | 58 (44.6) |
mRS>2 | 72 (55.4) |
mRS at 90 days categorized as bad outcome (N=130) | |
mRS 5–6 | 35 (26.9) |
mRS<5 | 95 (73.1) |
Post TICI flow (N=141) | |
0 | 7 (5.0) |
1 | 5 (3.6) |
2A | 20 (14.2) |
2B | 60 (42.6) |
3 | 49 (34.8) |
Post TICI flow categorized as good flow (N=141) | |
0–2A | 32 (22.7) |
2B–3 | 109 (77.3) |
Clinically significant event N=138) | |
Yes | 6 (4.4) |
No | 132 (95.7) |
Procedural complications (N=141) | |
Yes | 13 (9.2) |
No | 128 (90.8) |
Hemorrhage (N=141) | |
Yes | 24 (17.0) |
No | 117 (83.0) |
Hyperdense MCA (N=141) | |
Yes | 92 (65.3) |
No | 49 (34.8) |
Not all patients had clot length or Hounsfield Unit measurements.
IA, intra-arterial; IV, intravenous; MCA, middle cerebral artery; mRS, modified Rankin Scale; TICI, Thrombolysis In Cerebral Ischemia; tPA, tissue plasminogen activator.